Welcome to our dedicated page for Braveheart Bio SEC filings (Ticker: BRVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Braveheart Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Braveheart Bio's regulatory disclosures and financial reporting.
Braveheart Bio, Inc. director David Charles Lubner reported acquiring equity in two ways. On 2026-08-07, he purchased 55,555 shares of Common Stock at $18.00 per share in a direct open-market or private transaction, bringing his directly held common shares to 55,555. On 2026-08-05, he also received a grant of stock options for 60,000 shares of Common Stock with an exercise price of $18.00 per share, expiring on 2036-08-04. According to the grant terms, 1/36 of the option vests in substantially equal monthly installments on each monthly anniversary of July 23, 2026, contingent on his continuous service to the company.
Braveheart Bio, Inc. updated its governing documents in connection with completing its initial public offering. The company filed a Second Amended and Restated Certificate of Incorporation effective immediately prior to the IPO, authorizing 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. The new charter removes references to prior preferred series and eliminates stockholder ability to act by written consent or to call special meetings, shifting those powers to formal meeting processes.
The company’s Second Amended and Restated Bylaws, effective upon the Form S-1 registration statement’s effectiveness, establish procedures for stockholder actions at meetings, introduce an advance notice process for stockholder proposals and director nominations, and align bylaw provisions with the updated charter.
Braveheart Bio, Inc. is conducting an initial public offering of 21,250,000 shares of common stock at $18.00 per share, with expected gross proceeds before expenses of $382.5 million and net proceeds of about $351.2 million. Underwriters have a 30‑day option to purchase up to 3,187,500 additional shares. The stock is approved for listing on the Nasdaq Global Market under the symbol BRVE.
The company is a clinical‑stage biopharmaceutical business focused on hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB‑1893, a cardiac myosin inhibitor, has shown rapid LVOT gradient reduction and limited LVEF impact in Phase 2 studies run by its licensor Hengrui, and is being advanced into global Phase 3 trials in obstructive and non‑obstructive HCM.
Braveheart reported a $14.3 million net loss for the three months ended March 31, 2026 and had an accumulated deficit of $80.3 million, reflecting heavy R&D spending and no product revenue. Pro forma as adjusted for the IPO, cash and cash equivalents would be $431.8 million, to fund Phase 3 programs, supporting R&D, and general corporate purposes. The company highlights substantial risks typical for early‑stage biotech, including ongoing losses and the need for additional capital.
Braveheart Bio, Inc. reports that Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a more-than-10% owner through 7,420,091 shares of non-voting Series A preferred stock. This Preferred Stock is convertible into an equal number of common shares at the holder’s election and has no expiration date. All Preferred Stock will automatically convert into common stock immediately prior to the closing of Braveheart Bio’s initial public offering of its common stock.
Braveheart Bio, Inc. (BRVE) received an initial ownership report from OrbiMed-related entities. OrbiMed Private Investments IX, LP holds 9,132,420 shares of Series A Preferred Stock, convertible into the same number of Common shares on a one-for-4.38 basis, and 1,102,739 shares of Common Stock, all reported as indirect holdings. OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Braveheart Bio, Inc. received an initial beneficial ownership report from AH Bio Fund IV, L.P. and related entities regarding holdings in Series A Preferred Stock. This preferred stock is convertible into 9,132,420 shares of Common Stock on a 4.38-for-1 basis, at the option of the holder, and will convert automatically into that number of common shares immediately prior to the closing of the company’s initial public offering. The shares are held indirectly through AH Bio Fund IV, L.P. for itself and as nominee for several affiliated funds, with AH Equity Partners Bio IV, L.L.C. having sole voting and dispositive power. Marc Andreessen and Ben Horowitz, as managing members of AH Equity Partners Bio IV, may be deemed to share voting and dispositive power, while each reporting person disclaims group status and beneficial ownership except to the extent of any pecuniary interest.
Braveheart Bio, Inc. (BRVE) reports initial ownership by Forbion-related investment entities, each noted as a 10% owner. The positions include Series A Preferred Stock that is convertible into Common Stock on a one-for-4.38 basis and automatically converts into the stated numbers of Common shares immediately before the company’s initial public offering, with no expiration date. Reported holdings include both direct and indirect positions, and the reporting persons disclaim Section 16 beneficial ownership except to the extent of any pecuniary interest.